DANVERS, MA (PRWEB) - September 28, 2018 Cell Signaling Technology (CST) a leading provider of antibodies, kits, and services, announced that Genentech, a member of the Roche Group, has licensed proprietary PTMScan® technology from CST, further enabling discovery proteomics research.
The CST PTMScan technology is an immuno-affinity enrichment method that allows for the discovery of hundreds to thousands of novel sites of post-translational modifications (PTMs), including phosphorylation and ubiquitination. By combining the specificity of biomedical techniques with the dynamic range of proteomics methods, PTMScan provides a more focused approach to peptide enrichment compared to other strategies. Genentech currently utilizes PTMScan methodology to investigate and publish on a range of scientific research in multiple therapeutic areas.
“CST is pleased to have licensed PTMScan to Genentech to further enable their world class discovery and drug development research, while expanding the impact of PTMScan immuno-affinity enrichment technology. PTMScan is a powerful technology that can be leveraged to answer a variety of biological questions,” said Roberto Polakiewicz, Ph.D. Cell Signaling Technology, Chief Scientific Officer.
For more information about the application of PTMScan methodology in discovery proteomics research via profiling of post-translational modifications, please visit the webinar section of the CST’s proteomics web page www.cellsignal.com/proteomics.
Cell Signaling Technology (CST) is a private, family-owned company, founded by scientists and dedicated to providing high quality research tools to the biomedical research community. Our employees operate worldwide from our U.S. headquarters in Massachusetts, and our offices in the Netherlands, China, and Japan.
Cell Signaling Technology® and CST™ are trademarks of Cell Signaling Technology, Inc.
Rebecca J. Reppucci, MBA
Cell Signaling Technology, Inc.
Director of Marketing Communications